Original scientific paper
IMMUNOHISTOCHEMICAL EXPRESSION OF BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) IN TESTICULAR GERM CELL TUMORS
ANA MESIĆ
orcid.org/0000-0002-6144-2780
; Institute of Emergency Medicine, Krapina-Zagorje County, Krapina, Croatia
IVANA MILOŠEVIĆ
orcid.org/0000-0002-0369-930X
; University of Zagreb, School of Medicine, Zagreb, Croatia
VIBOR MILUNOVIĆ
; Merkur University Hospital, Department of Hematology, Zagreb, Croatia
MILAN MILOŠEVIĆ
orcid.org/0000-0001-9008-7645
; University of Zagreb, School of Medicine, Andrija Štampar School of Public Health, Zagreb, Croatia
MONIKA ULAMEC
orcid.org/0000-0002-4843-8154
; Sestre milosrdnice University Hospital Centre, Ljudevit Jurak Department of Pathology and Cytology, Zagreb, University of Zagreb, School of Medicine, Department of Pathology, Zagreb and Scientific Center of Excellence for Regenerative and Reproductive Med
BOŽO KRUŠLIN
orcid.org/0000-0002-0480-1687
; Sestre milosrdnice University Hospital Centre, Ljudevit Jurak Department of Pathology and Cytology, Zagreb, University of Zagreb, School of Medicine, Department of Pathology, Zagreb and Scientific Center of Excellence for Regenerative and Reproductive Med
Abstract
Brother of the Regulator of Imprinted Sites (BORIS) has a role in intracellular signalization and is important in epigenetic mechanism control, such as methylation/demethylation of DNA and histones. BORIS may deregulate some tumor suppressor genes. Immunohistochemical expression of BORIS was found in different tumors, some of them showing correlation with poor prognosis. The aim of this study was to determine immunohistochemical expression of BORIS in pure seminomas and different components of testicular mixed germ cell tumors (MGCT). In this study, immunohistochemical expression of BORIS in testicular germ cell tumors (TGCT) was analyzed. Staining intensity and percentage of positive staining cells were used to evaluate the level of expression. Tumor samples from 44 patients were analyzed; 26 pure seminomas and 18 MGCT. In MGCTs, seminoma component was found in 4, yolk sac in 7, teratoma in 11 and embryonal carcinoma in 13 samples. Expression of BORIS was strong in 80.8% of seminoma cases and in 76.9% of embryonal carcinoma component, 71.4% of yolk sac, 63.6% of teratoma component and 25% of seminomatous component of MGCT. In MGCT, positive correlation was found between BORIS expression in teratomatous component and presence of yolk sac component (
Keywords
BORIS; testicular germ cell tumors; immunohistochemistry; biomarkers
Hrčak ID:
216410
URI
Publication date:
30.1.2019.
Visits: 918 *